National and Kapodistrian University of Athens
Συγκριτική μελέτη συμβατικής αμφοτερικίνης Β και λιποσωμικής αμφοτερικίνης στην εμπειρική θεραπεία ουδετεροπενικών ασθενών με πυρετό αγνώστου αιτιολογίας
Abstract
dc:descriptionEmpirical antifungal treatment in patients with neutropenia and fever of unknown origin, which has not responded to the administration of broad-spectrum antimicrobial agents, has been established many years ago. The drug initially used was amphotericin B deoxycholate. Due to its toxicity, attempts were made to incorporate it in lipid formulations, in order to make the drug safer. One of the resulting lipid formulations was liposomal amphotericin B. The aim of this study was to compare the efficacy and safety of amphotericin B deoxycholate and liposomal amphotericin B, in the empirical treatment of patients with neutropenia and fever of unknown origin which has not responded to the administration of broad-spectrum antibiotics.. The patients were hospitalized in three hospital in Athens, Laikon, Hygeia and Metaxa. Inclusion criteria were age ?16, neutrophil count < 500/mm3 , fever ?380 C which did not respond to broad-spectrum antibiotics after 96 hours, underlying hematologic malignancy and absence of clinical, radiological or microbiological signs of infection. Patients who had been previously been treated with antifungal agents or who had creatinine values >2mg/100ml or transaminase values > 3 times above normal, were excluded from the study. The patients were randomized in two arms, in a ratio of 1:2, according to the administered drug: Amphotericin B deoxycholate (dAMB) 1mg/kg daily ΑmBisome (LAMB) 2mg/kg daily Sixty-nine patients were randomized: 23 received DAMB and 46 LAMB. There were no statistically significant differences between the two groups regarding demographic characteristics, underlying diseases, past medical history and findings on physical examination. Fever responded to the administration of the antifungal drug in 60% and 58% of patients who received LAMB and Damb respectively (p=1.00). Mortality was 30% in the LAMB group and 42% in the dAMB group. The difference was not statistically significant (p=0.434). Regarding breakthrough fungal infections, 12 cases were recorded in the LAMB group and 2 in the dAMB group (rates 28% and 8% respectively, p=0.086). SUMMARY Empirical antifungal treatment in patients with neutropenia and fever of unknown origin, which has not responded to the administration of broad-spectrum antimicrobial agents, has been established many years ago. The drug initially used was amphotericin B deoxycholate. Due to its toxicity, attempts were made to incorporate it in lipid formulations, in order to make the drug safer. One of the resulting lipid formulations was liposomal amphotericin B. The aim of this study was to compare the efficacy and safety of amphotericin B deoxycholate and liposomal amphotericin B, in the empirical treatment of patients with neutropenia and fever of unknown origin which has not responded to the administration of broad-spectrum antibiotics.. The patients were hospitalized in three hospital in Athens, Laikon, Hygeia and Metaxa. Inclusion criteria were age ?16, neutrophil count < 500/mm3 , fever ?380 C which did not respond to broad-spectrum antibiotics after 96 hours, underlying hematologic malignancy and absence of clinical, radiological or microbiological signs of infection. Patients who had been previously been treated with antifungal agents or who had creatinine values >2mg/100ml or transaminase values > 3 times above normal, were excluded from the study. The patients were randomized in two arms, in a ratio of 1:2, according to the administered drug: Amphotericin B deoxycholate (dAMB) 1mg/kg daily ΑmBisome (LAMB) 2mg/kg daily Sixty-nine patients were randomized: 23 received DAMB and 46 LAMB. There were no statistically significant differences between the two groups regarding demographic characteristics, underlying diseases, past medical history and findings on physical examination. Fever responded to the administration of the antifungal drug in 60% and 58% of patients who received LAMB and Damb respectively (p=1.00). Mortality was 30% in the LAMB group and 42% in the dAMB group. The difference was not statistically significant (p=0.434). Regarding breakthrough fungal infections, 12 cases were recorded in the LAMB group and 2 in the dAMB group (rates 28% and 8% respectively, p=0.086). The breakthrough infections were all due to Aspergillus sp. except one case of hepatosplenic candidiasis. The only parameter that was found to be different in the two groups was the rate of infusion related adverse events, which were 2% in the LAMB group and 31% in the dAMB group (p=0.001). In contrast, no significant difference was found in nephrotoxicity. In conclusion, this study didn’t show statistically significant difference of the efficacy of amphotericin B deoxycholate and liposomal amphotericin in the treatment of neutropenic patients with fever of unknown origin. The other similar studies of the literature have also reached the same conclusion. Regarding toxicity, the study found difference between the two groups only in infusion related toxicity. The non-significant difference in nephrotoxicity was attributed to the small number of patiens included in the study.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2010
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Skiada, Anna
- Σκιαδά, Άννα
Subjects
dc:subject × 16- Ουδετεροπενία
- Πυρετός αγνώστου αιτιολογίας
- Αμφοτερικίνη Β
- Λιποσωμική αμφοτερικίνη
- Εμπειρική θεραπεία
- Μυκητίαση
- Neutropenia
- Fever of unknown origin
- Amphotericin B
- Liposomal amphotericin
- Empirical treatment
- Fungal infections
- Ιατρική και Επιστήμες Υγείας
- Κλινική Ιατρική
- Medical and Health Sciences
- Clinical Medicine
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/25843